Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population
复制标题
DOI：
10.1183/09031936.06.00110005
复制
发表时间：
2006-06-01
影响因子：
24.3
通讯作者：
Leufkens, H. G. M.
中科院分区：
文献类型：
--
作者：
van de Garde, E. M. W.;Souverein, P. C.;Leufkens, H. G. M.
本研究的目的是评估是否使用血管紧张素转换酶（ACE）抑制剂与社区获得性肺炎（CAP）住院治疗的风险降低一般，基本上是白色population.Data从荷兰PHARMO记录链接系统。病例定义为首次因CAP入院的患者。研究人群包括1,108名首次因CAP住院的患者和3,817名匹配的对照组。在调整了几个混杂因素后，ACE抑制剂的使用与肺炎发生率的降低无关（调整后的比值比（OR）1.12; 95%置信区间（CI）0.88-1.43）。此外，在糖尿病、呼吸系统疾病、心力衰竭或后两种疾病患者中未观察到显著相关性。此外，使用平衡评分分层调整治疗对肺炎风险的影响也显示，在不同分层中，ACE抑制剂的使用与肺炎风险之间无显著相关性（总体调整后OR 1.09; 95%CI 0.87-1.36）。与之前在亚洲人群中的发现相反，目前的作者无法证实血管紧张素转换酶抑制剂对一般人群（主要是白色人群）肺炎风险的有益作用。
The aim of the present study was to assess whether the use of anglotensin-converting enzyme (ACE) inhibitors is associated with a decreased risk of hospitalisation for community-acquired pneumonia (CAP) in a general, essentially white population.Data were obtained from the Dutch PHARMO Record Linkage System. Cases were defined as patients with a first hospital admission for CAP. For each case, up to four population controls were matched by age and sex.The study population comprised 1,108 patients with a first hospital admission for CAP and 3,817 matched controls. After adjusting for several confounders, ACE inhibitor use was not associated with a decreased incidence of pneumonia (adjusted odds ratio (OR) 1.12; 95% confidence interval (CI) 0.88-1.43). Additionally, no significant association was observed in patients with diabetes, respiratory diseases, heart failure, or patients with both of the last two conditions. Furthermore, adjustment of treatment effects on pneumonia risk using stratification on balancing score also showed no significant association between ACE inhibitor use and pneumonia risk within the different strata (overall adjusted OR 1.09; 95% Cl 0.87-1.36).In contrast with previous findings in Asian populations, the current authors were not able to confirm the beneficial effect of angiotensin-converting enzyme inhibitors on pneumonia risk in a general, essentially white population.